Neuroinflammation and Comorbidity of Pain and Depression
Abstract
Comorbid depression and chronic pain are highly prevalent in individuals suffering from physical illness. Here, we critically examine the possibility that inflammation is the common mediator of this comorbidity, and we explore the implications of this hypothesis. Inflammation signals the brain to induce sickness responses that include increased pain and negative affect. This is a typical and adaptive response to acute inflammation. However, chronic inflammation induces a transition from these typical sickness behaviors into depression and chronic pain. Several mechanisms can account for the high comorbidity of pain and depression that stem from the precipitating inflammation in physically ill patients. These mechanisms include direct effects of cytokines on the neuronal environment or indirect effects via downregulation of G protein–coupled receptor kinase 2, activation of the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase that generates neurotropic kynurenine metabolites, increased brain extracellular glutamate, and the switch of GABAergic neurotransmission from inhibition to excitation. Despite the existence of many neuroimmune candidate mechanisms for the co-occurrence of depression and chronic pain, little work has been devoted so far to critically assess their mediating role in these comorbid symptoms. Understanding neuroimmune mechanisms that underlie depression and pain comorbidity may yield effective pharmaceutical targets that can treat both conditions simultaneously beyond traditional antidepressants and analgesics.
Acknowledgments
The authors thank Jennifer Hsieh and Aiat Radwan for editorial assistance on this manuscript.
Abbreviations
| ASC stands for ; ASC | apoptosis-associated speck-like protein containing a CARD |
| AMPA | α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid |
| BBB | blood-brain barrier |
| CCI | chronic constriction injury |
| CFA | complete Freund’s adjuvant |
| CGRP | calcitonin gene–related peptide |
| CNS | central nervous system |
| CSF | cerebrospinal fluid |
| D4 | Delpire 4 |
| DAMP | damage-associated molecular pattern |
| DRG | dorsal root ganglion |
| FST | forced swim test |
| GPCR | G protein–coupled receptor |
| GRK2 | G protein–coupled receptor kinase 2 |
| HDRS | Hamilton Depressive Rating Scale |
| IDO | indoleamine 2,3-dioxygenase |
| IFN | interferon |
| IL | interleukin |
| LPS | lipopolysaccharide |
| MAPKs | mitogen-activated protein kinases |
| MDD | major depressive disorder |
| NBQX | 3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione |
| NF-κB | nuclear factor κB |
| NMDA | N-methyl-d-aspartate |
| NTS | nucleus of the tractus solitarius |
| PAMP | pathogen-associated molecular pattern |
| PBMCs | peripheral blood mononuclear cells |
| SNI | spinal nerve injury |
| SSRI | selective serotonin reuptake inhibitor |
| TDO | tryptophan 2,3-dioxygenase |
| TLR | Toll-like receptor |
| TNF | tumor necrosis factor |
| TRPV1 | transient receptor potential cation chloride channel subfamily V member 1 |
Authorship Contributions
Wrote or contributed to the writing of the manuscript: Walker, Kavelaars, Heijnen, Dantzer.
Footnotes
This work was supported by the University of Texas MD Anderson Cancer Center and National Institutes of Health National Institute of Neurological Disorders and Stroke [Grants R01-NS073939; and R01-NS074999]. The work of A.K. is also supported by a STARS [“Science and Technology Acquisition and Retention”] award of the University of Texas System.
R.D. is a consultant with Ironwood Pharma (Cambridge, MA).
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.




